Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors

NCT00106353 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00106353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2005
Completion date
January 31, 2012
Enrollment
71 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, neoplasms